Teva Pharmaceutical Industries

TEVA · TEL

$40.85−$0.46 (−1.11%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $41.31

Latest news

Press releaseOct 20, 8:00 AM ETGlobe Newswire
UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease
Press releaseOct 12, 5:45 PM ETGlobe Newswire
Teva to Host R&D Day on Wednesday, November 11 in New York City
NewsOct 9, 12:28 PM ETVandana Singh
FDA Approves Teva's New Once-Monthly Schizophrenia Injection
Press releaseOct 9, 7:00 AM ETGlobe Newswire
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia
Press releaseOct 2, 8:00 AM ETGlobe Newswire
Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients
Press releaseOct 2, 8:00 AM ETGlobe Newswire
Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome
Press releaseSep 30, 4:32 PM ETGlobe Newswire
TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness
Press releaseSep 28, 4:00 PM ETGlobe Newswire
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
Press releaseSep 23, 4:45 PM ETGlobe Newswire
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
Press releaseSep 23, 4:45 PM ETGlobe Newswire
Teva Releases Q3 2026 Aide Memoire
Press releaseSep 18, 4:30 PM ETGlobe Newswire
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
NewsSep 15, 8:49 AM ETDylan Berman
Teva's Shares Now Trade Directly on the NYSE — Here's What Else Changed
Press releaseSep 14, 9:03 AM ETPRNewswire
Temporal Raises $550 Million in Series E Round: NYSE Content Update
Press releaseSep 14, 8:03 AM ETGlobe Newswire
Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
NewsSep 2, 10:13 AM ETVandana Singh
Teva Reports Significant Prevention Of Gluten-Induced Damage in New Study
NewsSep 2, 10:08 AM ETDylan Berman
Teva Stock Rises After TEV '408 Meets Primary Endpoint in Celiac Disease Study
NewsSep 1, 4:57 AM ETNamrata Sen
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
NewsAug 28, 11:06 AM ETAkanksha Bakshi
BioXcel Stock Plunges: Chapter 11 Filing Triggers Teva Stalking Horse Bid
NewsAug 20, 9:30 AM ETVandana Singh
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
Press releaseAug 11, 8:00 AM ETGlobe Newswire
Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy
NewsJul 29, 1:57 PM ETVandana Singh
Teva's Innovative Drug Portfolio Fuels Growth as Company Raises Outlook, Transitions to Direct NYSE Listing
NewsJul 29, 7:01 AM ET
Teva Pharmaceutical Indus Q2 Adj. EPS $0.02 Misses $0.25 Estimate, Sales $4.142B Beat $4.047B Estimate
Press releaseJul 29, 7:00 AM ETGlobe Newswire
Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy
Press releaseJul 9, 8:45 AM ETBusiness Wire
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
NewsJul 8, 6:47 PM ETChris Katje
Bill Ackman Says Next $1 Trillion Company Will Come From Israel – ‘Imagine if Silicon Valley Was a Country’
NewsJul 7, 2:21 PM ETVandana Singh
Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial
NewsJun 16, 8:50 AM ET
FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid Overdose
NewsMay 1, 1:35 PM ET
10 Health Care Stocks With Whale Alerts In Today's Session
NewsApr 29, 1:52 PM ETVandana Singh
Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan
NewsApr 29, 9:12 AM ET
Teva Pharmaceutical Indus Q1 2026 Earnings Call Transcript
NewsApr 29, 7:11 AM ET
Earnings Scheduled For April 29, 2026
NewsApr 29, 7:01 AM ET
Teva Pharmaceutical Indus Q1 Adj. EPS $0.53 Beats $0.48 Estimate, Sales $3.982B Beat $3.810B Estimate
Press releaseApr 29, 7:00 AM ETGlobe Newswire
Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution
NewsApr 16, 11:37 AM ET
FDA Takes Step Forward on Testosterone Therapy for Men
NewsApr 1, 1:36 PM ETVandana Singh
Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda
NewsFeb 20, 10:00 AM ET
Price Over Earnings Overview: Teva Pharmaceutical Indus
NewsFeb 5, 2:00 PM ET
A Look Into Teva Pharmaceutical Indus Inc's Price Over Earnings
NewsJan 30, 10:08 AM ETVandana Singh
Novo Nordisk Sued Over Alleged Scheme To Delay Generic Victoza In Favor Of Ozempic
NewsJan 28, 1:01 PM ETPiero Cingari
Gold Rallies To $5,300, Memory Stocks Go Wild: What's Moving Markets Wednesday?
NewsJan 28, 12:22 PM ETVandana Singh
Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook
Press releaseJan 28, 7:00 AM ETGlobe Newswire
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
NewsJan 27, 11:02 AM ET
Earnings Preview For Teva Pharmaceutical Indus
NewsJan 2, 8:58 AM ETAvi Kapoor
Top 2 Health Care Stocks That May Crash In Q1
NewsDec 24, 9:51 AM ETVandana Singh
Teva Pharmaceutical Stock Hits 52-Week High On Credit Ratings Lift
NewsDec 10, 11:47 AM ET
Teva Removes Over 200 Improper Patent Listings Under Pressure From FTC; FTC Investigation Prompts Teva Request For Removal Of Patents From Orange Book, Paving The Way For Generic Competition
NewsNov 19, 11:26 AM ETVandana Singh
Jury Convicts Done Global Founder In Adderall Distribution Scheme: WSJ Report
NewsNov 5, 11:30 AM ETVandana Singh
Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook
Press releaseNov 5, 7:00 AM ETGlobe Newswire
Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
NewsOct 15, 9:34 AM ETAkanksha Bakshi
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures
NewsOct 9, 9:31 AM ETVandana Singh
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs
Press releaseJul 30, 7:00 AM ETGlobe Newswire
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
Press releaseJun 26, 11:44 AM ETPRNewswire
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
Press releaseMay 7, 7:00 AM ETGlobe Newswire
Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved
Press releaseJan 29, 7:00 AM ETGlobe Newswire
Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease

Teva to Host R&D Day on Wednesday, November 11 in New York City

FDA Approves Teva's New Once-Monthly Schizophrenia Injection

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients

Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome

TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness

Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

Teva Releases Q3 2026 Aide Memoire

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

Teva's Shares Now Trade Directly on the NYSE — Here's What Else Changed

Temporal Raises $550 Million in Series E Round: NYSE Content Update

Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy

Teva Reports Significant Prevention Of Gluten-Induced Damage in New Study

Teva Stock Rises After TEV '408 Meets Primary Endpoint in Celiac Disease Study

Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President

BioXcel Stock Plunges: Chapter 11 Filing Triggers Teva Stalking Horse Bid

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy

Teva's Innovative Drug Portfolio Fuels Growth as Company Raises Outlook, Transitions to Direct NYSE Listing

Teva Pharmaceutical Indus Q2 Adj. EPS $0.02 Misses $0.25 Estimate, Sales $4.142B Beat $4.047B Estimate

Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

Bill Ackman Says Next $1 Trillion Company Will Come From Israel – ‘Imagine if Silicon Valley Was a Country’

Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial

FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid Overdose

10 Health Care Stocks With Whale Alerts In Today's Session

Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan

Teva Pharmaceutical Indus Q1 2026 Earnings Call Transcript

Earnings Scheduled For April 29, 2026

Teva Pharmaceutical Indus Q1 Adj. EPS $0.53 Beats $0.48 Estimate, Sales $3.982B Beat $3.810B Estimate

Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

FDA Takes Step Forward on Testosterone Therapy for Men

Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda

Price Over Earnings Overview: Teva Pharmaceutical Indus

A Look Into Teva Pharmaceutical Indus Inc's Price Over Earnings

Novo Nordisk Sued Over Alleged Scheme To Delay Generic Victoza In Favor Of Ozempic

Gold Rallies To $5,300, Memory Stocks Go Wild: What's Moving Markets Wednesday?

Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Earnings Preview For Teva Pharmaceutical Indus

Top 2 Health Care Stocks That May Crash In Q1

Teva Pharmaceutical Stock Hits 52-Week High On Credit Ratings Lift

Teva Removes Over 200 Improper Patent Listings Under Pressure From FTC; FTC Investigation Prompts Teva Request For Removal Of Patents From Orange Book, Paving The Way For Generic Competition

Jury Convicts Done Global Founder In Adderall Distribution Scheme: WSJ Report

Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS

SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components

The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth